ClinicalTrials.gg
TerminatedNCT03738423Updated Jun 10, 2022Results posted

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of REGN3500 and REGN3500-Matching Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Terminated at 90 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-10.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals — 1 open to participants now, 2 under way, none of them phase 3. Dermatitis, Atopic · Regeneron Pharmaceuticals.

Enrollment
16th of 25
129 · median 194
Started
2018
with 3 others
Phase 2
8 of 30
none open now
Registered
23rd of 30
by date

Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 2, and was the 23rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD.

Secondary objectives are to:

  • Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in adult patients with moderate-to-severe AD
  • Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe AD
  • Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD
03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Moderate
  • Severe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Chronic AD, according to American Academy of Dermatology Consensus Criteria (Eichenfield, 2014), that has been present for at least 3 years before the screening visit
  2. Eczema Area and Severity Index (EASI) score ≥16 at the screening and baseline visits
  3. IGA score ≥3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at screening and baseline visits
  4. ≥10% Body surface area (BSA) of AD involvement at the screening and baseline visits
  5. Documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments are medically inadvisable

Key Exclusion Criteria:

  1. Participation in a prior anti-Interleukin (IL)-33 medication clinical study
  2. Treatment with an drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the baseline visit
  3. Having used any of the following treatments within 4 weeks before the baseline visit or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment:

    1. /immunomodulating drugs (eg, systemic , cyclosporine, mycophenolate-mofetil, Interferon-gamma (IFN-γ), Janus kinase inhibitors, azathioprine, methotrexate, etc)
    2. Phototherapy for AD
  4. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit
  5. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
  6. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit
  7. Known or suspected history of immunosuppression
  8. History of (HIV) infection or positive HIV serology at screening
  9. Positive with surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or virus antibody (HCV Ab) at the screening visit
  10. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Treatment 1

    Drug: REGN3500 · Drug: REGN3500-Matching Placebo

  • Experimental
    Treatment 2

    Drug: REGN3500 · Drug: REGN3500-Matching Placebo

  • Experimental
    Treatment 3

    Drug: REGN3500 · Drug: REGN3500-Matching Placebo

  • Experimental
    Treatment 4

    Drug: REGN3500 · Drug: REGN3500-Matching Placebo

  • Experimental
    Treatment 5

    Matching placebo

    Drug: REGN3500-Matching Placebo

Interventions

  • Administered subcutaneous (SC)

  • DrugREGN3500-Matching Placebo

    Administered subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 was reported. Values after first rescue treatment were set to missing.

    Time frame: Week 16

  2. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  3. Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  4. Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  5. Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  6. Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  7. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported.

    Time frame: Week 16

  8. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  9. Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing IGA score at Week 16 were counted as non-responders.

    Time frame: Week 16

  10. Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  11. Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported.

    Time frame: Week 16

  12. Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Time frame: Week 16

  13. Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

    Time frame: Week 16

  14. Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  15. Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

    Time frame: Week 16

  16. Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  17. Time to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)

    Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?"

    Time frame: Week 16

  18. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

    The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Week 16

  19. Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

    BSA affected by AD will be assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and will be reported as a percentage of all major body sections combined. The proportion assigned to different body regions is different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children).

    Time frame: Week 16

  20. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16

    Adverse Event (AE): any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE): any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included: serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 16 were reported.

    Time frame: Up to week 16

  21. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36

    AE: any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. SAE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included both Serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 36 were reported.

    Time frame: Up to week 36

  22. Serum Concentration of Functional REGN3500

    Serum Concentration of Functional REGN3500 was reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32 and 36

  23. Number of Participants With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)

    Treatment-Emergent (TE) ADA was defined as any positive post baseline assay response when baseline results were negative or missing. Treatment-Emergent ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period \[based on nominal sampling time\], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). Number of participants with positive treatment-emergent anti-REGN3500 antibodies (ADA) were reported. Here, "Number of Participants Analyzed" signifies those participants who were evaluable for this endpoint.

    Time frame: Up to week 36

07

Results

Posted Jun 10, 2022
Limitations and caveats
The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Participants discontinued study drug and transitioned into the post-treatment follow-up period. As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed.

Participant flow

A total of 238 participants were screened at centers in North America (United States of America and Canada), Europe (Czech Republic, Germany, Hungary, Spain, and Poland), and Asia Pacific (Republic of Korea, Japan, and Australia). Out of which, 129 participants were randomized in this study.

Participant flow — Overall Study
MilestonePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Started2526272526
Treated2526262426
Completed1113141011
Not completed1413131515
Withdrew: Withdrawal by subject91291210
Withdrew: Lack of efficacy31112
Withdrew: Lost to follow-up10110
Withdrew: Protocol violation10001
Withdrew: Physician decision00101
Withdrew: Death00001
Withdrew: Randomized but never treated00110

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 was reported. Values after first rescue treatment were set to missing.

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-33.5 ± 41.81-57.9 ± 31.65-52.7 ± 46.64-80.0 ± 10.54-54.0 ± 36.80
PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-18.9 ± 52.01-46.0 ± 45.35-48.7 ± 44.66-67.0 ± 28.74-56.1 ± 35.32
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1630.071.471.410055.6
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 1625.060.062.577.860.0
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1620.028.628.671.444.4
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 1616.730.025.055.640.0
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1610.014.328.628.633.3
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 168.320.025.022.230.0
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Score on a scalePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-7.8 ± 10.225-14.64 ± 8.489-14.81 ± 12.614-18.19 ± 6.298-13.79 ± 9.534
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Score on a scalePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-4.10 ± 13.079-12.07 ± 11.764-13.83 ± 12.000-15.15 ± 8.299-14.68 ± 9.410
SecondaryPercentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing IGA score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 1610.00.028.642.933.3
SecondaryPercentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 168.30.025.033.330.0
SecondaryAbsolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Score on a scalePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-0.53 ± 1.583-2.95 ± 3.791-4.22 ± 2.372-3.34 ± 2.628-3.12 ± 3.896
SecondaryAbsolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

Time frame:
Week 16
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Score on a scalePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-0.51 ± 1.430-2.56 ± 3.563-4.19 ± 2.198-2.69 ± 2.799-3.12 ± 3.896
SecondaryPercent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-6.1 ± 20.65-31.6 ± 39.01-53.1 ± 29.65-43.1 ± 36.42-32.2 ± 47.46
SecondaryPercent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-5.9 ± 18.62-27.5 ± 39.24-52.8 ± 27.47-33.9 ± 38.71-32.2 ± 47.46
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 160.042.957.128.650.0
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of participantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 160.040.062.522.250.0
SecondaryTime to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)

Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?"

Time frame:
Week 16
Reported as:
Mean · Weeks
Time to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)
WeeksPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Time to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)6.6 ± 3.717.1 ± 4.747.1 ± 5.026.0 ± 4.295.8 ± 3.50
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16-12.7 ± 25.41-31.4 ± 22.67-39.2 ± 38.39-42.40 ± 20.00-40.5 ± 29.00
SecondaryAbsolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

BSA affected by AD will be assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and will be reported as a percentage of all major body sections combined. The proportion assigned to different body regions is different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children).

Time frame:
Week 16
Reported as:
Mean · Percentage of change
Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16
Percentage of changePlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16-2.74 ± 17.854-15.19 ± 16.509-11.43 ± 22.022-22.16 ± 15.783-20.99 ± 16.161
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16

Adverse Event (AE): any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE): any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included: serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 16 were reported.

Time frame:
Up to week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16
ParticipantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Participants with TEAEs91312915
Participants with Serious TEAEs00002
Participants with AESIs00100
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36

AE: any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. SAE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included both Serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic or acute allergic reactions; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; severe infections; any clinical endoparasitosis; Conjunctivitis, keratitis, or blepharitis; significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 36 were reported.

Time frame:
Up to week 36
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36
ParticipantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Participants with TEAEs1114141315
Participants with Serious TEAEs00012
Participants with AESIs00100
SecondarySerum Concentration of Functional REGN3500

Serum Concentration of Functional REGN3500 was reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32 and 36
Reported as:
Mean · Milligrams per Liter (mg/L)
Serum Concentration of Functional REGN3500
Milligrams per Liter (mg/L)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
Baseline (Week 0)—NA ± NA0.157 ± 0.800NA ± NANA ± NA
Week 2—3.29 ± 2.707.35 ± 5.6521.4 ± 9.8322.0 ± 11.0
Week 4—2.33 ± 1.825.14 ± 3.7314.3 ± 7.0537.9 ± 15.2
Week 8—1.41 ± 1.999.27 ± 5.3323.3 ± 10.451.4 ± 20.7
Week 12—2.63 ± 2.208.74 ± 6.3730.3 ± 12.057.7 ± 26.3
Week 16—1.05 ± 0.73310.6 ± 4.9135.2 ± 17.360.8 ± 33.3
Week 20—0.523 ± 0.4415.03 ± 3.9312.4 ± 6.5829.8 ± 23.5
Week 24—0.170 ± 0.1572.23 ± 1.247.14 ± 5.2212.1 ± 14.4
Week 28—0.0838 ± 0.1091.08 ± 0.8133.49 ± 2.766.70 ± 7.64
Week 32—0.0171 ± 0.04840.625 ± 0.5601.93 ± 1.373.73 ± 5.41
Week 36—NA ± NA0.299 ± 0.2500.960 ± 0.7411.02 ± 1.31
SecondaryNumber of Participants With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)

Treatment-Emergent (TE) ADA was defined as any positive post baseline assay response when baseline results were negative or missing. Treatment-Emergent ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period \[based on nominal sampling time\], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). Number of participants with positive treatment-emergent anti-REGN3500 antibodies (ADA) were reported. Here, "Number of Participants Analyzed" signifies those participants who were evaluable for this endpoint.

Time frame:
Up to week 36
Reported as:
Count of participants · Participants
Number of Participants With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)
ParticipantsPlacebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2W
TE Persistent00000
TE Transient00000
TE Indeterminate00000

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 36) regardless of seriousness or relationship to investigational product (IP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/25 (0%)0/25 (0%)7/25 (28%)
R3500 30 mg Q8W0/26 (0%)0/26 (0%)11/26 (42.3%)
R3500 100 mg Q4W0/26 (0%)0/26 (0%)9/26 (34.6%)
R3500 300 mg Q4W0/24 (0%)1/24 (4.2%)8/24 (33.3%)
R3500 300 mg Q2W1/26 (3.8%)2/26 (7.7%)10/26 (38.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo Q2WR3500 30 mg Q8WR3500 100 mg Q4WR3500 300 mg Q4WR3500 300 mg Q2W
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/260/261/240/26
Gastroenteritis norovirusInfections and infestations0/250/260/260/241/26
Road traffic accidentInjury, poisoning and procedural complications0/250/260/260/241/26
Most frequent other events
Most frequent other events
EventPlacebo Q2WR3500 30 mg Q8WR3500 100 mg Q4WR3500 300 mg Q4WR3500 300 mg Q2W
Dermatitis atopicSkin and subcutaneous tissue disorders3/258/265/265/246/26
NasopharyngitisInfections and infestations0/252/264/262/243/26
CellulitisInfections and infestations0/251/260/262/241/26
NauseaGastrointestinal disorders1/250/260/262/240/26
Urinary tract infectionInfections and infestations2/250/260/261/240/26
BronchitisInfections and infestations0/250/260/260/242/26
ToothacheGastrointestinal disorders1/250/261/260/242/26
HeadacheNervous system disorders1/251/260/260/242/26
Oedema peripheralGeneral disorders0/252/260/260/241/26

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants and was based on the treatment allocated (as randomized).

Age, Continuous
Age, Continuous(Years)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2WTotal
Mean36.6 ± 14.2236.0 ± 16.4137.0 ± 14.4835.6 ± 12.5638.8 ± 15.4436.8 ± 14.51
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2WTotal
Female141312141568
Male111315111161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2WTotal
Hispanic or Latino124007
Not Hispanic or Latino2424222523118
Unknown or Not Reported001034
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2WTotal
American Indian or Alaska Native000000
Asian985111043
Native Hawaiian or Other Pacific Islander000000
Black or African American3423214
White131420111472
More than one race000000
Unknown or Not Reported000000
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(Scores on a scale)Placebo Q2WREGN3500 30 mg Q8WREGN3500 100 mg Q4WREGN3500 300 mg Q4WREGN3500 300 mg Q2WTotal
Mean30.3 ± 11.8829.8 ± 12.0033.6 ± 11.0127.7 ± 10.6832.7 ± 15.1330.9 ± 12.25
08

Study locations

90 sites
  • Regeneron Study Site
    Birmingham, Alabama 35209, United States
  • Regeneron Study Site
    Phoenix, Arizona 85006, United States
  • Regeneron Study Site
    Scottsdale, Arizona 85259, United States
  • Regeneron Study Site
    Tucson, Arizona 85718, United States
  • Regeneron Study Site
    Little Rock, Arkansas 72205, United States
  • Regeneron Study Site
    Fountain Valley, California 92708, United States
  • Regeneron Study Site
    Fremont, California 94538, United States
  • Regeneron Study Site
    Oceanside, California 92056, United States
  • Regeneron Study Site
    Sacramento, California 95815, United States
  • Regeneron Study Site
    Santa Monica, California 90404, United States
  • Regeneron Study Site
    Jacksonville, Florida 32256, United States
  • Regeneron Study Site
    Macon, Georgia 31217, United States
  • Regeneron Study Site
    Skokie, Illinois 60077, United States
  • Regeneron Study Site
    Evansville, Indiana 47714, United States
  • Regeneron Study Site
    Overland Park, Kansas 66215, United States
  • Regeneron Study Site
    Louisville, Kentucky 40202, United States
  • Regeneron Study Site
    Louisville, Kentucky 40217, United States
  • Regeneron Study Site
    Louisville, Kentucky 40241, United States
  • Regeneron Study Site
    Saint Joseph, Michigan 49085, United States
  • Regeneron Study Site
    Minneapolis, Minnesota 55402, United States
  • Regeneron Study Site
    Las Vegas, Nevada 89148, United States
  • Regeneron Study Site
    Lebanon, New Hampshire 03756, United States
  • Regeneron Study Site
    New York, New York 10022, United States
  • Regeneron Study Site
    Wilmington, North Carolina 28405, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45231, United States
  • Regeneron Study Site
    Norman, Oklahoma 73071, United States
  • Regeneron Study Site
    North Charleston, South Carolina 29420, United States
  • Regeneron Study Site
    San Antonio, Texas 78218, United States
  • Regeneron Study Site
    San Antonio, Texas 78229, United States
  • Regeneron Study Site
    San Antonio, Texas 78258, United States
  • Regeneron Study Site
    Norfolk, Virginia 23502, United States
  • Regeneron Study Site
    Kogarah, 2217, Australia
  • Regeneron Study Site
    Melbourne, 3002, Australia
  • Regeneron Study Site
    Calgary, Alberta T2G 1B1, Canada
  • Regeneron Study Site
    Hamilton, Ontario L8S 1G5, Canada
  • Regeneron Study Site
    Hamilton, Ontario L8S 4K1, Canada
  • Regeneron Study Site
    Toronto, Ontario M5N 1E3, Canada
  • Regeneron Study Site
    Windsor, Ontario N8X 2G1, Canada
  • Regeneron Study Site
    Verdun, Quebec H4G 3E7, Canada
  • Regeneron Study Site
    Brno, 602 00, Czechia
  • Regeneron Study Site
    Nachod, 547 01, Czechia
  • Regeneron Study Site
    Ostrava, 702 00, Czechia
  • Regeneron Study Site
    Praha, 130 00, Czechia
  • Regeneron Study Site
    Bad Bentheim, 48455, Germany
  • Regeneron Study Site
    Berlin, 10117, Germany
  • Regeneron Study Site
    Berlin, 12459, Germany
  • Regeneron Study Site
    Frankfurt, 60590, Germany
  • Regeneron Study Site
    Hamburg, 20537, Germany
  • Regeneron Study Site
    Hanau, 63450, Germany
  • Regeneron Study Site
    Ibbenburen, 49477, Germany
  • Regeneron Study Site
    Leipzig, 04103, Germany
  • Regeneron Study Site
    Lubeck, 23538, Germany
  • Regeneron Study Site
    Munchen, 80337, Germany
  • Regeneron Study Site
    Munster, 48149, Germany
  • Regeneron Study Site
    Tubingen, 72076, Germany
  • Regeneron Study Site
    Tuebingen, 72076, Germany
  • Regeneron Study Site
    Witten, 58453, Germany
  • Regeneron Study Site
    Oroshaza, Bekes 5900, Hungary
  • Regeneron Study Site
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Regeneron Study Site
    Budapest, 84-88, Hungary
  • Regeneron Study Site
    Chuo, 409-3898, Japan
  • Regeneron Study Site
    Hiroshima, 734-8551, Japan
  • Regeneron Study Site
    Kanagawa, 252-0392, Japan
  • Regeneron Study Site
    Kyoto, 602-8566, Japan
  • Regeneron Study Site
    Kyoto, 606-8507, Japan
  • Regeneron Study Site
    Shizuoka, 420-8630, Japan
  • Regeneron Study Site
    Shizuoka, 430-0929, Japan
  • Regeneron Study Site
    Wakayama, 641-8510, Japan
  • Regeneron Study Site
    Yamanashi, 400-8506, Japan
  • Regeneron Study Site
    Bucheon-Si, 14584, Korea, Republic of
  • Regeneron Study Site
    Busan, 49241, Korea, Republic of
  • Regeneron Study Site
    Gyeonggi-do, 16499, Korea, Republic of
  • Regeneron Study Site
    Incheon, 21431, Korea, Republic of
  • Regeneron Study Site
    Incheon, 21565, Korea, Republic of
  • Regeneron Study Site
    Seoul, 02841, Korea, Republic of
  • Regeneron Study Site
    Seoul, 06591, Korea, Republic of
  • Regeneron Study Site
    Seoul, 06973, Korea, Republic of
  • Regeneron Study Site
    Seoul, 07441, Korea, Republic of
  • Regeneron Study Site
    Krakow, 30-033, Poland
  • Regeneron Study Site
    Lodz, 90-436, Poland
  • Regeneron Study Site
    Szczecin, 71-434, Poland
  • Regeneron Study Site
    Warszawa, 01-817, Poland
  • Regeneron Study Site
    Warszawa, 02-953, Poland
  • Regeneron Study Site
    Wroclaw, 51-318, Poland
  • Regeneron Study Site
    Wroclaw, 51-685, Poland
  • Regeneron Study Site
    Barakaldo, 48903, Spain
  • Regeneron Study Site
    Cordoba, 14004, Spain
  • Regeneron Study Site
    Madrid, 28041, Spain
  • Regeneron Study Site
    Santiago de Compostela, 15706, Spain
  • Regeneron Study Site
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2020, 16 months.

Results were first posted in Jun 2022, 2 years 2 months after primary completion. A results delay was requested in Mar 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2018
First posted
Nov 13, 2018
StartActual
Nov 13, 2018
Primary completionActual
Mar 13, 2020
CompletionActual
Jul 24, 2020
Results delay requested
Mar 12, 2021
Results first posted
Jun 10, 2022
Last update
Jun 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03738423
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Nov 13, 2018
Primary completion
Mar 13, 2020
Completion
Jul 24, 2020
Results posted
Jun 10, 2022
Last update
Jun 10, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion